Testing TQB2102 for HER2-positive bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, TQB2102, for people with advanced bile duct cancer that has HER2 protein markers. It aims to see if the drug can help when previous treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have advanced bile duct cancer that cannot be removed by surgery
- Your cancer has HER2 protein at high levels (3+ or 2+ with extra testing)
- You have had 1 or 2 previous treatments that stopped working
- You are healthy enough for daily activities (ECOG score 0 or 1)
- If you can become pregnant, you must use effective birth control during and for 6 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, TQB2102, for people with HER2-negative breast cancer that has spread and no longer responds to standard treatments. The goal is to see if the drug can shrink tumors or slow the cancer.
This trial tests a new drug called TQB2102 against a standard treatment (Kadcyla) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those whose cancer has worsened after previous HER2-targeted therapy.
This trial tests a new drug called TQB2102 given before surgery for HER2-positive breast cancer. The goal is to see if it can shrink the tumor enough to allow a successful surgery.
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
This trial tests a new combination of drugs (TQB2102, benmelstobart, and pembrolizumab) with or without chemotherapy for people with HER2-positive gastroesophageal cancer that cannot be removed by surgery or has spread. It aims to see if this combination is more effective than current treatments.
This trial tests a new medicine called TQB2930 for people with advanced breast cancer that is HER2-positive. It is for those who have already had at least two prior anti-HER2 treatments and are willing to also receive chemotherapy chosen by their doctor.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.